MTYKA
LIVE

Serial Number

97661691

Owner

Mirati Therapeutics, Inc.

Attorney

Marilyn F. Kelly

Filing Date

Nov 3, 2022

Add to watchlist:

No watchlists yet
View on USPTO

MTYKA Trademark

Serial Number: 97661691

MTYKA is a trademark filed by Mirati Therapeutics, Inc. on November 3, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Mirati Therapeutics, Inc. (34 trademarks)

San Diego, CA 92121

Entity Type: 03

Trademark Details

Filing Date

November 3, 2022

Registration Date

Not Registered

Published for Opposition

January 9, 2024

Goods & Services

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of bladder cancer; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of renal cancer; pharmaceutical preparations for the treatment of renal cell carcinoma; pharmaceutical preparations for the treatment of squamous cell carcinoma; pharmaceutical preparations for the treatment of head and neck squamous cell carcinoma; pharmaceutical preparations for the treatment of oral cavity squamous cell carcinoma; pharmaceutical preparations for the treatment of colorectal cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of bladder cancer; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of renal cancer; pharmaceuticals comprising small molecules for the treatment of renal cell carcinoma; pharmaceuticals comprising small molecules for the treatment of squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of head and neck squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of oral cavity squamous cell carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal cancer; pharmaceutical products for the treatment of cancer; pharmaceutical products for use in oncology; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of bladder cancer; pharmaceutical products for the treatment of lung cancer; pharmaceutical products for the treatment of renal cancer; pharmaceutical products for the treatment of renal cell carcinoma; pharmaceutical products for the treatment of squamous cell carcinoma; pharmaceutical products for the treatment of head and neck squamous cell carcinoma; pharmaceutical products for the treatment of oral cavity squamous cell carcinoma; pharmaceutical products for the treatment of colorectal cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors

Research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 12, 2026 EXRA
SOU EXTENSION 4 GRANTED
Feb 12, 2026 EX4G
SOU EXTENSION 4 FILED
Feb 12, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 12, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 27, 2025 EXRA
SOU EXTENSION 3 GRANTED
Aug 26, 2025 EX3G
SOU EXTENSION 3 FILED
Aug 26, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Aug 26, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 2 GRANTED
Mar 4, 2025 EX2G
SOU EXTENSION 2 FILED
Mar 4, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 4, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 20, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 20, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 20, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 20, 2024 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 27, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 27, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 27, 2024 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 5, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 9, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 9, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 20, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 4, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 1, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 30, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 30, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 7, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 7, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 9, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 9, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 9, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 8, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 22, 2022 NWOS
NEW APPLICATION ENTERED
Nov 7, 2022 NWAP